Hinge Health's Q3 Revenue Jumps 52% as MSK Leader Bets on Migraine and GI Expansion

Hinge Health's third-quarter results give investors a clear signal: the core business is accelerating, not plateauing, and management is using that strength to fund a riskier diversification play.

The digital musculoskeletal care company posted $235 million in third-quarter revenue, up 52% from $154 million a year earlier and ahead of its own guidance range of $223 million to $225 million. Adjusted earnings came in at 66 cents per share, topping Wall Street's 60-cent estimate. Non-GAAP income from operations jumped 154% to $77.2 million.

Those are not the numbers of a company that needs to chase new categories out of desperation. They're the numbers of a company with a cash-generative core business looking to compound its advantage.

CEO Daniel Perez made that distinction explicit on Monday's earnings call. "We're not taking our eye off the ball in MSK. I think we're actually widening our lead on MSK," he told analysts, before pivoting to the company's push into neurology and gastrointestinal care. "We're not starting from scratch in each new category. We're extending a platform that's already proven into conditions that are often connected to the ones we already treat."

The MSK Engine Still Has Room to Run

Client growth tells the underlying story. Hinge Health ended September with 3,270 clients, up 28% year-over-year. Last-twelve-month calculated billings rose 54% to $960 million, compared with $624 million a year ago. Gross margin expanded to 87%, from 82% in the same quarter last year. Free cash flow hit $113 million, a 51% margin, leaving the company with $359 million in cash on the balance sheet.

Perez argues the MSK opportunity remains "massively underpenetrated." His estimate: 88% of lives within Hinge's addressable markets have yet to be won. Musculoskeletal conditions rank among the leading drivers of disability and healthcare spend in the U.S., and most Americans still lack access to a digital MSK solution. Whether that 88% figure proves durable as competitors enter the space is a fair question, but the billings growth suggests Hinge is capturing share faster than the market is maturing.

That strength is funding the diversification. Hinge's $105 million cash acquisition of GI startup Cylinder Health in August is the clearest example. Since the deal was announced, the company's MSK client base is up almost 30% year-over-year, while the GI Care Program's client base has grown roughly 40%, according to Perez. The logic behind bundling conditions is clinical as much as commercial: nearly one in two people with GI conditions also have MSK pain, and 70% of people with migraine also report a GI condition. Perez also pointed to GLP-1 adoption as a tailwind for GI demand, noting that gastrointestinal side effects tied to the weight-loss drugs have become "a growing pain point for employers and health plans."

The migraine program, still in early access, is producing numbers worth watching. Perez cited a 23% reduction in monthly migraine days, a 28% reduction in migraine duration (roughly five hours), and clinically meaningful improvement in just over half of surveyed members. More than 800 clients, representing 9 million lives, now have access to the program, roughly double the prior quarter. The GI integration timeline is longer: Hinge is targeting summer 2027 for a fully integrated product on its existing app infrastructure, with meaningful revenue contribution expected in 2028 once a full sales cycle plays out.

Management raised full-year guidance on the back of the quarter. Hinge now expects 2026 revenue between $879 million and $881 million, up from a prior range of $856 million to $860 million, implying roughly 50% year-over-year growth at the midpoint. Non-GAAP income from operations is now projected at $266 million to $268 million, up 123% year-over-year, with operating margin near 30%.

Commercial momentum backs up the raised targets. Chief Commercial Officer Aaryn Pure said the company closed three new Fortune 15 clients in the quarter and has already secured verbal agreements on more lives this year than it closed in all of 2025, itself a record year. More than 10 million lives across over 800 clients now have access to multiple Hinge products. Small and midsize businesses, a market Hinge entered just a year ago, delivered nearly 1 million SMB lives through Q3, and some health plan and TPA partners are moving toward embedding Hinge on an opt-out basis within their SMB books, a distribution advantage Pure called a "first-mover" position.

The company also confirmed a leadership change: President Jim Pursley will step down effective January 1 and move to Hinge's board, with Pure assuming leadership of the commercial organization.

Key Risks

The diversification strategy is not without exposure. Perez signaled Hinge intends to keep acquiring, including in hardware, a category most digital health software companies avoid. "I absolutely firmly believe you will not automate care delivery without also investing in hardware," he said, pointing to the company's FDA-cleared Enso wearable as proof of execution. He framed the approach as organic-first, with M&A used to accelerate timelines through "small tuck-ins of technology and a team." That's a reasonable capital allocation philosophy, but hardware integration carries manufacturing, regulatory and supply chain risk that pure software expansion does not.

Valuation is the other consideration. Shares are up nearly 150% year-to-date. William Blair's Ryan Daniels noted the stock now trades at roughly 11 times 2027 adjusted gross profit, a premium to mature, high-margin healthcare IT peers. Daniels still called the risk/reward "compelling" given growth momentum and potential upside to operating income and free cash flow estimates, but the multiple leaves less room for execution missteps, particularly in GI care, where meaningful revenue is still two years out.

What Investors Should Watch

The MSK business remains the valuation anchor, and its 54% billings growth and 87% gross margin suggest the core franchise is far from mature. The real swing factor for the stock over the next six to eight quarters will be whether migraine and GI care convert early clinical signals into the kind of client and lives growth that MSK has already demonstrated. Integration execution on Cylinder, the pace of hardware M&A, and whether SMB and health-plan embedded distribution scale as management expects are the metrics that will determine if this becomes a genuine multi-condition platform or a well-funded MSK leader testing adjacent markets.